These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 33973194)

  • 61. Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.
    Shirzad M; Nourigorji M; Sajedi A; Ranjbar M; Rasti F; Sourani Z; Moradi M; Mostafa Mir S; Memar MY
    Int Immunopharmacol; 2022 Oct; 111():109161. PubMed ID: 35998506
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
    Mendoza-Pinto C; García-Carrasco M; Munguía Realpozo P; Méndez-Martínez S
    Reumatol Clin (Engl Ed); 2021 Oct; 17(8):431-436. PubMed ID: 34625144
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Current status in cellular-based therapies for prevention and treatment of COVID-19.
    Hattab D; Amer MFA; Mohd Gazzali A; Chuah LH; Bakhtiar A
    Crit Rev Clin Lab Sci; 2023 Aug; 60(5):321-345. PubMed ID: 36825325
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Consensus statement and recommendations on the treatment of COVID-19: 2021 update.
    Ko HK; Yu WK; Pan SW; Chen WC; Yang KY; Lin YT; Wang FD; Yang MH; Chen YM;
    J Chin Med Assoc; 2022 Jan; 85(1):5-17. PubMed ID: 34524227
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy.
    Kędzierska-Kapuza K; Zielińska D; Matejak-Górska M; Durlik M
    Transplant Proc; 2021 May; 53(4):1194-1201. PubMed ID: 33892930
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.
    Farhangnia P; Dehrouyeh S; Safdarian AR; Farahani SV; Gorgani M; Rezaei N; Akbarpour M; Delbandi AA
    Int Immunopharmacol; 2022 Aug; 109():108786. PubMed ID: 35483235
    [TBL] [Abstract][Full Text] [Related]  

  • 67. COVID-19 in cancer patients: risk, clinical features, and management.
    Liu C; Zhao Y; Okwan-Duodu D; Basho R; Cui X
    Cancer Biol Med; 2020 Aug; 17(3):519-527. PubMed ID: 32944387
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.
    Long B; Chavez S; Carius BM; Brady WJ; Liang SY; Koyfman A; Gottlieb M
    Am J Emerg Med; 2022 Jun; 56():158-170. PubMed ID: 35397357
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Is there a role for immune-enhancing therapies for acutely ill patients with coronavirus disease 2019?
    Wittebole X; Montiel V; Mesland JB
    Curr Opin Crit Care; 2021 Oct; 27(5):480-486. PubMed ID: 34334626
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2.
    Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Brooks AES
    Expert Rev Clin Immunol; 2022 Jun; 18(6):557-565. PubMed ID: 35510369
    [TBL] [Abstract][Full Text] [Related]  

  • 71. COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy.
    Rahman MH; Akter R; Behl T; Chowdhury MAR; Mohammed M; Bulbul IJ; Elshenawy SE; Kamal MA
    Curr Pharm Des; 2020; 26(41):5224-5240. PubMed ID: 32660401
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant.
    Lazzari L; Oltolini C; Ciceri F; Giglio F
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34667047
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immune-based therapeutic approaches in COVID-19.
    Moeinafshar A; Yazdanpanah N; Rezaei N
    Biomed Pharmacother; 2022 Jul; 151():113107. PubMed ID: 35594701
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.
    Langerbeins P; Eichhorst B
    Acta Haematol; 2021; 144(5):508-518. PubMed ID: 33631756
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunobiology and immunotherapy of COVID-19: A clinically updated overview.
    Esmaeilzadeh A; Elahi R
    J Cell Physiol; 2021 Apr; 236(4):2519-2543. PubMed ID: 33022076
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiviral combination therapies for persistent COVID-19 in immunocompromised patients.
    Focosi D; Maggi F; D'Abramo A; Nicastri E; Sullivan DJ
    Int J Infect Dis; 2023 Dec; 137():55-59. PubMed ID: 37778409
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.
    Çınar OE; Sayınalp B; Aladağ Karakulak E; Avşar Karataş A; Velet M; İnkaya AÇ; Ersoy Ortaç NE; Öcal S; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe Oİ
    Transfus Apher Sci; 2020 Oct; 59(5):102821. PubMed ID: 32487513
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Current treatment challenges in the COVID-19 pandemic.
    Patrucco F; Gavelli F; Fagoonee S; Solidoro P; Undas A; Pellicano R
    Pol Arch Intern Med; 2021 Sep; 131(9):854-861. PubMed ID: 34590451
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hypothesis: Immunotherapy by Selective Convalescent Blood Engineering to Stifle Diseases like COVID-19.
    Mukherjee AP
    Int J Med Sci; 2021; 18(15):3389-3394. PubMed ID: 34522165
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In quest of a new therapeutic approach in COVID-19: the endocannabinoid system.
    Lucaciu O; Aghiorghiesei O; Petrescu NB; Mirica IC; Benea HRC; Apostu D
    Drug Metab Rev; 2021 Nov; 53(4):478-490. PubMed ID: 33683968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.